Year: 2011
Type: editorial
Abstract: (HR) of 1.28 (90% CI, 0.85 to 1.93). 8 The updated 5-year RFR is 1.34%. The upper limit of the 90% CI for 5-year RFR exceeds 3% (90%CI,0.7%to3.5%),andtheHRisgreaterthan1.0(HR,1.28; 90%CI,0.83to1.89). 7 Therefore,thedifferenceinRFRiswideningin a direction favoring RT. These results imply that a 2-year RFR end point was probably too short (consistent with surveillance studies in which 30% of relapses occurred after 2 years), and carboplatin may
Source: Journal of Clinical Oncology
Authors: George J. Bosl, Sujata Patil
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2029967023